The role of mTOR signaling pathway in premalignant and malignant cervical lesions

European Journal of Gynaecological Oncology

Volumn 36, Issue 1, 2015, Pages 36-43

  Andrikopoulou, M ^a   Salakos, N ^a   Deligeoroglou, E ^a   Pafiti, A ^a   Boutas, I ^a   Nikitakis, N ^b   Sklavounou, A ^b   Creatsas, G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cervical cancer; HSIL; LSIL; mTOR signaling pathway

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRECANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CANCER; CHEMISTRY; METABOLISM; PHOSPHORYLATION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PHOSPHOPROTEINS; PHOSPHORYLATION; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UTERINE CERVICAL NEOPLASMS;

EID: 84924658565     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: 10.12892/ejgo2563.2015     Document Type: Article

References (25)

1. Rosai J.: "Rosai and Ackerman's surgical pathology". 9th ed. Philadelphia: Mosby, Elsevier Inc., 2004 1532.
2. Molinolo A.A., Amornphimoltham P., Squarize C.H., Castilho R.M., Patel V., Gutkind J.S.: "Dysregulated molecular networks in head and neck carcinogenesis". Oral Oncol., 2009, 45, 324.
3. Gao N., Flynn D.C., Zhang Z., Zhong X.S., Walker V., Liu K.J., et al.: "G1 cell cycle progression and the expression of Gl cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells". Am. J. Physiol. Cell Physiol, 2004, 287, C281.
4. Gao N., Zhang Z., Jiang B.H., Shi X.: "Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer". Biochem. Biophys. Res. Commun., 2003, 310, 1124.
5. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., et al.: "Randomized phase JJ study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma". J. Clin. Oncol., 2004, 22, 909.
6. Hudes A.: "phase III, randomized, 3 arm study of temsirolinus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor risk patients with advanced renal cell carcinoma". Proc. Am. Soc. Clin. Oncol., 2006, 24, 2S.
7. Cassinelli G., Zuco V., Gatti L., Lanzi C., Zaffaroni N., Colombo D., Perego P.: "Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells". Curr. Med. Chem., 2013, 20, 1923.
8. Diaz-Padilla I., Duran I., Clarke B.A., Oza A.M.: "Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer". Cancer Treat Rev., 2012, 38, 767.
9. Kim T.J., Lee J.W., Song S.Y., Choi J.J., Choi C.H., Kim B.G., et al.: "Increased expression of pAKT is associated with radiation resistance in cervical cancer". Br. J. Cancer, 2006, 94, 1678.
10. Faried L.S., Faried A., Kanuma T., Sano T., Nakazato T., Tamura T., et al.: "Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy". Oncol. Rep., 2006, 16, 57.
11. Vega F., Medeiros L.J., Leventaki V., Atwell C., Cho-Vega J.H., Tian L., et al.: "Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma". Cancer Res., 2006, 66, 6589.
12. Tian L., Claret F.X., Rassidakis G.Z.: "Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma". Cancer Res., 2006, 66, 6589.
13. Ji J., Zheng P.S.: "Activation of mTOR signaling pathway contributes to survival of cervical cancer cells". Gynecol. Oncol., 2010, 117, 103.
14. Feng W., Duan X., Liu J., Xiao J., Brown R.E.: "Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions". Int. J. Clin. Exp. Pathol, 2009, 2, 249.
15. Tamburrino A., Molinolo A.A., Salerno P., Chernock R.D., Raffeld M., Xi L., et al.: "Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases". Clin. Cancer Res., 2012, 18, 3532.
16. Foster K.G., Fingar D.C.: "Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony". J. Biol Chem., 2010 285, 14071.
17. Grell P., Fabian P., Khoylou M., Radova L., Slaby O., Hrstka R., et al.: "Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab". Int. J. Oncol., 2012, 41, 1204.
18. Xia S., Zhao Y., Yu S., Zhang M.: "Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells". Cancer Biother. Ratiopharm., 2010, 25, 317.
19. Sahin K., Tuzcu M., Basak N., Caglayan B., Kilic U., Sahin F., Kucuk O.: "Sensitization of cervical cancer cells to cisplatin by genistein: the role of NFΚB and Akt/mTOR signaling pathways". J. Oncol., 2012, 461562. doi:10.1155/2012/461562. Epub 2012 Sep 27.
20. Korolenkova L.I., Stepanova E.V., Ermilova V.D., Baryshnikov Alu, Griuzgin V.V.: "pAkt expression in cervical intraepithelial neoplasia (CIN) and in microinvasive cervical cancer". Vopr. Onkol., 2012, 58, 777.
21. Ruvinsky I., Meyuhas O.: "Ribosomal protein S6 phosphorylation: from protein synthesis to cell size". Trends Biochem. Sci., 2006, 31, 342.
22. Benavente S., Vergés R., Hermosilla E., Fumanal V., Casanova N., Garcia A., et al.: "Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy". Int. J. Radiat. Oncol Biol. Phys., 2009, 75, 1316.
23. Hay N., Sonenberg N.: "Upstream and downstream of mTOR". Genes Dev., 2004, 18, 1926.
24. Kim M.K., Kim T.J., Sung CO, Choi C.H., Lee J.W., Kim B.G., Bae D.S.: "High expression of mTOR is associated with radiation resistance in cervical cancer". J. Gynecol. Oncol., 2010, 21, 181.
25. Oh K.J., Kalinina A., Park N.H., Bagchi S.: "Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein". J. Virol., 2006, 80, 7079.